{"id":7800,"date":"2026-02-24T06:08:28","date_gmt":"2026-02-24T06:08:28","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/glp-1-semaglutide\/"},"modified":"2026-04-09T14:26:07","modified_gmt":"2026-04-09T21:26:07","slug":"glp-1-s","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/glp-1-s\/","title":{"rendered":"GLP-1 S \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to GLP-1 S product page<\/a><\/p>\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on this compound \u2014 for educational purposes only<\/p>\n

\nHow does GLP-1 S’s acylation affect its structural profile? (for educational purposes only)<\/summary>\n
\n

GLP-1 S incorporates a C-18 fatty di-acid chain (octadecanedioic acid) attached to lysine at position 26 via a mini-PEG linker (\u03b3Glu-2\u00d7OEG spacer). This acyl moiety binds non-covalently to serum albumin with high affinity, creating a circulating depot that shields the peptide from renal clearance and enzymatic degradation. The resulting structural profile reflects the compound’s modified acylation strategy. The spacer length and fatty acid chain were specifically optimized to balance albumin binding strength with receptor accessibility. Research compound \u2014 not for human use.<\/p>\n

Citation: Lau J, Bloch P, Sch\u00e4ffer L, et al. “Discovery of the Long-Acting Glucagon-Like Peptide-1 (GLP-1) Analogue GLP-1 S.” J Med Chem.<\/em> 2015;58(18):7370-7380. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nHow does GLP-1 S’s structure compare to native GLP-1(7-37)? (for educational purposes only)<\/summary>\n
\n

GLP-1 S shares 94% amino acid sequence homology with endogenous human GLP-1(7-37), differing at only two positions. An \u03b1-aminoisobutyric acid (Aib) substitution at position 8 confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, which normally inactivates native GLP-1 within 2-3 minutes. Arginine replaces lysine at position 34 to prevent unwanted fatty acid conjugation at that site, directing acylation exclusively to Lys26. These minimal modifications preserve full GLP-1 receptor binding potency while dramatically extending the molecule’s circulating persistence. Research compound \u2014 not for human use.<\/p>\n

Citation: Lau J, Bloch P, Sch\u00e4ffer L, et al. “Discovery of the Long-Acting Glucagon-Like Peptide-1 (GLP-1) Analogue GLP-1 S.” J Med Chem.<\/em> 2015;58(18):7370-7380. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nWhat is GLP-1 S’s GLP-1 receptor binding selectivity? (for educational purposes only)<\/summary>\n
\n

GLP-1 S is a selective GLP-1 receptor agonist with no meaningful affinity for the GIP receptor, glucagon receptor, or other class B GPCRs. In radioligand binding assays, GLP-1 S displaces GLP-1 from its receptor with an IC\u2085\u2080 comparable to native GLP-1, demonstrating preserved binding potency despite structural modifications. The Aib8 substitution and C-18 fatty di-acid acylation do not substantially alter receptor binding affinity or cAMP generation efficacy at GLP-1R. This selectivity profile distinguishes GLP-1 S from multi-receptor agonists such as GLP-2 T. Research compound \u2014 not for human use.<\/p>\n

Citation: Lau J, Bloch P, Sch\u00e4ffer L, et al. “Discovery of the Long-Acting Glucagon-Like Peptide-1 (GLP-1) Analogue GLP-1 S.” J Med Chem.<\/em> 2015;58(18):7370-7380. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nHow was GLP-1 S’s structure optimized during discovery? (for educational purposes only)<\/summary>\n
\n

GLP-1 S’s design followed systematic structure-activity relationship studies starting from liraglutide (C-16 acyl chain, once-daily). Researchers evaluated fatty acid chain lengths (C-16 to C-20), spacer compositions (\u03b3Glu, OEG combinations), and acylation positions to optimize the balance between albumin binding affinity, GLP-1R potency, and pharmacokinetic half-life. The C-18 di-acid with \u03b3Glu-2\u00d7OEG spacer at Lys26 yielded the optimal profile: 3-fold stronger albumin affinity than liraglutide while maintaining equivalent receptor activation potency. Over 50 analogs were synthesized and characterized during this optimization process. Research compound \u2014 not for human use.<\/p>\n

Citation: Lau J, Bloch P, Sch\u00e4ffer L, et al. “Discovery of the Long-Acting Glucagon-Like Peptide-1 (GLP-1) Analogue GLP-1 S.” J Med Chem.<\/em> 2015;58(18):7370-7380. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

To compare published studies with Panda batch documentation, review Reportes de laboratorio (COAs)<\/a>, Calidad y pruebas<\/a>, la gu\u00eda para evaluar materiales de investigaci\u00f3n<\/a>, o nuestras Preguntas frecuentes<\/a>.<\/p>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to GLP-1 S product page Research Library Published research on this compound \u2014 for educational purposes only How does GLP-1 S’s acylation affect its structural profile? (for educational purposes only) GLP-1 S incorporates a C-18 fatty di-acid chain (octadecanedioic acid) attached to lysine at position 26 via a mini-PEG linker (\u03b3Glu-2\u00d7OEG spacer). This […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7800","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7800"}],"version-history":[{"count":3,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7800\/revisions"}],"predecessor-version":[{"id":8631,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7800\/revisions\/8631"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}